Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Aim(s): The aim was to describe the characteristics of patients and advanced somatostatin receptor–positive neuroendocrine tumours (TNE) treated with 177Lu-DOTATATE (PRRT) and to evaluate the efficacy and safety.
Materials and methods: The data come from the SEPTRALU national study in which a multidisciplinary team of 18 centers participate. Survival was evaluated using the Kaplan-Meier method and Cox proportional risk regression. Toxicity was recorded according to CTCAEv3.0 criteria.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Alberto Carmona-Bayonas
, Mitjavila Casanovas M
, Belló P
, Percovich J C
, Prieto A
, Arbizu J
, Field C
, Muro M A
, Del Olmo M
, Castellón M
, Pubul V
, Jimenez-Fonseca P
To read results and conclusion, please login ...
Further abstracts you may be interested in